Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
株式のランク #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
株価
$150.78
最終同期: 2026-09-18
時価総額
$187.20B
変化(1日)
-0.08%
変化(1年)
32.15%
US
取引 Gilead Sciences, Inc. (GILD)

カテゴリー

Gilead Sciences, Inc.(GILD)のP/S比率
September 2026 時点のP/S比率 TTM: 5.97
Gilead Sciences, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 5.97 です。2024 年末時点でのP/S比率は 4.01 でした。
Gilead Sciences, Inc. の P/S 比率の履歴(2000 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 5.97 15.00%
2025 5.19 29.46%
2024 4.01 7.44%
2023 3.73 -5.59%
2022 3.95 18.24%
2021 3.34 12.60%
2020 2.97 -19.31%
2019 3.68 0.19%
2018 3.67 2.31%
2017 3.59 13.67%
2016 3.16 -30.48%
2015 4.54 -21.25%
2014 5.76 -43.76%
2013 10.25 78.72%
2012 5.73 51.64%
2011 3.78 -3.10%
2010 3.90 -30.11%
2009 5.58 -36.72%
2008 8.82 -12.66%
2007 10.10 2.59%
2006 9.85 -16.34%
2005 11.77 3.14%
2004 11.41 -15.54%
2003 13.51 -5.12%
2002 14.24 -46.77%
2001 26.76 38.69%
2000 19.29 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
13.45 125.34%
US
6.55 9.80%
US
7.18 20.32%
US
4.66 -21.95%
CH
5.39 -9.74%
US